In conversation with...: Recent Episodes
The Lancet Oncology
Márcia Costa, Senior Editor at The Lancet Oncology, and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.
5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer.
Click here to read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00122-1/fulltext
Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of osteosarcoma and Ewing sarcoma.
Click here to read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00141-5/fulltext
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission.
To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce.
To read the full commission click here: https://doi.org/10.1016/S1470-2045(26)00065-3
Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.
Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).
Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext
Tell us what you thought about this episode
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranosticsto learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026.
To learn more:
European Congress of Radiology: https://www.myesr.org/congress/
The Lancet Medical Imaging & Theranostics: https://www.thelancet.com/medical-imaging-theranostics
For presubmission enquiries and other questions email imaging@lancet.com
To submit your manuscript: https://www2.cloud.editorialmanager.com/thelancetimaging/default2.aspx
Join The Lancet Medical Imaging & Theranostics’ editorial team for a Lancet Webinar dedicated to helping you publish with The Lancet Medical Imaging & Theranostics https://hubs.li/Q042sbn40
Find us on LinkedIn and Bluesky @lancetimaging.bsky.social
Tell us what you thought about this episode
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranosticsto learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext
Tell us what you thought about this episode
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranosticsto learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology.
Read the full Reviews:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research
and
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9 for Expert Recommendations for the Conduct and Appraisal of Qualitative Research in Oncology
and the reviews in Lancet Haematology 2026 https://doi.org/10.1016/S2352-3026(25)00321-7
and eClinicalMedicine https://doi.org/10.1016/j.eclinm.2025.103736
Tell us what you thought about this episode
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranosticsto learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA.
Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00593-5/fulltext
Tell us what you thought about this episode
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranosticsto learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.
Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.
Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission
And comment: Re-establishing human-centred care
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.
Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next.
Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Click here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.
Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.
They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?rss=yes?dgcid=buzzsprout_icw_podcast_September_25_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.
In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in meningiomas, assess their association with patient outcomes, and discuss the potential implications for patient management and the classification of these tumours.
You can read the two Articles here:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00267-0/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonc
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00422-X/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments.
See the whole Series here:
https://www.thelancet.com/series-do/cancer-control-in-middle-east?dgcid=buzzsprout_icw_podcast_lanonccanceremro25_lanonc
Watch the Series video here: https://youtu.be/t3AGdouXpqg
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference.
If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167
Articles discussed in this podcast episode include:
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo
asco2025
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.
They discuss the disease burden of advanced melanoma with BRAF mutations, the key findings from the EBIN trial, and the future implications of the study findings, especially for a select sub-population of patients with advanced melanoma.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00133-0/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial.
This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risks, patient experiences, and the potential implications for clinical practice and health policy.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00100-7/fulltext?dgcid=buzzsprout_tlv_podcast_30-04-25_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00405-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries.
Read the full Series:
https://www.thelancet.com/series/cancer-care-in-saarc-countries?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.
Read the full Articles here:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.
Read the Commission:
https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.
Read the full Policy Review:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.
Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.
Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00072-4/fulltext?dgcid=buzzsprout_icw_podcast_lanonc_lancet
Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)
Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.
Read the full article:
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer
Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.
Read the full article:
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis
Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.
Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.
Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Read the full Review:
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment
Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.
Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
Ignace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers.
Visit the Series hub:
Gynaecological cancers
David J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe.
Read the full article:
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe
Wilfred Ngwa (Harvard Medical School, Boston, MA, USA; Johns Hopkins University, Baltimore, MD, USA; ICT University, Yaounde, Cameroon), Beatrice Wiafe-Addai (Peace and Love Hospital, Kumasi, Ghana), and David Kerr (University of Oxford, Oxford, UK) discuss the Lancet Oncology Commission on cancer in sub-Saharan Africa.
Georgios Lyratzopoulos (Institute of Epidemiology & Health Care at University College London, London, UK) discusses his population-based study on risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission.
Read the full article:
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation)
Lisa Iezzoni (Massachusetts General Hospital, Boston, MA, USA) discusses her Series paper on disabilities and cancer and Jordan Marchak (Children’s Healthcare of Atlanta, Atlanta, GA, USA) discusses her Review on surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors.
Read the full articles:
Cancer detection, diagnosis, and treatment for adults with disabilities
Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors
Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.
Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression
Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.
Read the full articles:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302)
Rebecca Fitzgerald (University of Cambridge, Cambridge, UK) discusses her Article on the use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance.
Read the full article:
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance
Elysia Alvarez (UC Davis Comprehensive Cancer Center, Sacramento, USA) discusses her Article on the analysis of the global burden of adolescent and young adult cancer in 2019.
Read the full article:
The global burden of adolescent and young adult cancer in 2019
Aju Mathew (Malankara Orthodox Syrian Church Medical College and Hospital, Kerala, India) discusses his Review on financial toxicity in cancer care in India.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00468-X/fulltext
David Pinato (Imperial College London, Hammersmith Hospital, London, UK) discusses his Article on prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection.
Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00573-8/fulltext
James Glasbey (UK NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK) discusses his Article on the effect of COVID-19 pandemic lockdowns on planned cancer surgery.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00493-9/fulltext
Manju Sengar (Tata Memorial Centre, India) and Christopher Booth (Queen’s University Cancer Research Institute, Canada) discuss their Article on the comparison between cancer drugs deemed essential by oncologists and those included in the WHO Essential Medicines List.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00463-0/fulltext
Susannah Stanway (UK Global Cancer Network), Richard Cowan (Christie NHS Foundation Trust, UK), Danielle Rodin (Princess Margaret Cancer Centre, Canada), and Miriam Mutebi (Aga Khan University Hospital, Kenya) discuss the Global Cancer Control Networks Series on how high-income countries, particularly the UK and Canada, can help with cancer control in low-income and middle-income countries.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00374-0/fulltext
Harriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00279-5/fulltext
Rafael Cardoso and Hermann Brenner (German Cancer Research Center, Heidelberg, Germany) discuss their recent paper on colorectal cancer incidence, mortality, and stage distribution in Europe.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00199-6/fulltext
Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext
Roberto Orecchia (European Institute of Oncology IRCCS) discusses the ELIOT trial on intraoperative irradiation for early breast cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00080-2/fulltext
Hedvig Hricak (Memorial Sloan Kettering Cancer Center), Andrew Scott (Olivia Newton-John Cancer Research Institute), Rifat Atun (Harvard TH Chan School of Public Health), and May Abdel-Wahab (International Atomic Energy Agency) discuss the latest Lancet Oncology’s Commission on Medical Imaging and Nuclear Medicine.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30751-8/fulltext
Ariana Znaor, International Agency for Research on Cancer, discusses her Article on breast and cervical cancers stage distributions in ten newly independent states of the former Soviet Union.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30674-4/fulltext
Sathira Perera (University of New South Wales, Australia) discusses his (and colleagues) Articles on the global use of cancer surgery.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30675-6/fulltext
Geke Hospers (University Medical Center Groningen, The Netherlands) discusses the RAPIDO trial Article published in The Lancet Oncology.
Annie Young (University of Warwick, UK) and Julia Challinor (University of California San Francisco, USA) present their two-paper Series on Oncology Nursing.
Robert Hiatt (University of California San Francisco, USA) discusses his and Naomi Beyeler’s (same University) Review on climate change and cancer.
Paul Sargos (Institut Bergonié, France) discusses the GETUG-AFU 17 trial and Andrew Kneebone (Royal North Shore Hospital and University of Sidney, Australia) the RAVES trial.
Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses the Review in The Lancet Oncology on molecular profiling of neuroendocrine tumours to predict response to peptide receptor radionuclide therapy.
Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a pooled analysis in The Lancet Oncology on the role of larotrectinib in patients with TRK fusion-positive solid tumours.
Ken Herrman (University Hospital Essen, Essen, Germany) discusses a Review in The Lancet Oncology on the role of injectable radiopharmaceuticals with anti-tumour effects.
Corneel Coens and Madeline Pe discuss recommendations from the SISAQOL Consortium for the analysis of patient-reported outcomes, published in a Policy Review in The Lancet Oncology.
Monica Koo (University College London, London, UK) discusses an Article in The Lancet Oncology on presenting symptoms of cancer and stage at diagnosis in patients in England.
Rifat Atun (Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA) discusses a Review in The Lancet Oncology on global patterns in public and philanthropic funding for childhood cancer research with Senior Editor Márcia Costa.
Partha Basu (International Agency for Research on Cancer, Lyon, France) discusses a Policy Review in The Lancet Oncology on cervical cancer prevention efforts in India.
David Palma and Anthony Nichols discuss the findings from their ORATOR trial on radiotherapy or robotic surgery for oropharyngeal squamous cell carcinoma.
New Zealand’s new interim Cancer Control Agency director, Diana Sarfati, discusses a series of five papers exploring cancer control in small island nations.
Eric Deutsch (Gustave Roussy Comprehensive Cancer Center, Villejuif, France) presents The Lancet Oncology’s latest series on advances in radioimmunotherapy for cancer.
Georgina Long (The University of Sydney, Sydney, NSW, Australia) discusses three papers from The Lancet Oncology on neoadjuvant approaches for melanoma treatment.
Jens Hillengass discusses the new International Myeloma Working Group consensus guidelines on optimal use of imaging methods for monoclonal plasma cell disorders.
Kee Yuan Ngiam (National University Hospital Singapore, Singapore) discusses a duo of papers exploring big data and machine-learning algorithms for healthcare delivery and pathology in oncology.
CS Pramesh discusses ten low-value or harmful practises that should be avoided in cancer care in India.
Bianca Hoeben discusses the latest guidelines from the SIOPE radiotherapy working group on vertebral radiotherapy dose in paediatric patients.
Anna Bibby joins The Lancet Oncology to discuss recent developments in the treament of malignant plural mesothelioma.
Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Talía Malagón discusses her modelling study which assesses the age at which to stop cervical cancer screening in older women and the remaining lifetime risk of cervical cancer.
Andre Ilbawi talks about his global analysis of available national cancer control plans with The Lancet Oncology.
A review in The Lancet Oncology asks whether patient reported outcomes in RCTs are consistent across their analysis, reporting, and interpretation. Author Madeline Pe discusses the findings.
Eva Steliarova-Foucher joins The Lancet Oncology to discuss the Europe-wide Automated Childhood Cancer Information System, and the increase in cancer incidence rates among children and adolescents.
Mark Souweidane joins The Lancet Oncologyto discuss his dose-escalation study, assessing a convection-enhanced delivery for diffuse intrinsic pontine glioma.
Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.
Fabio Conforti talks to The Lancet Oncology about a meta-analysis showing that a patient's sex can affect the efficacy of cancer immunotherapy.
Paul Kluetz from the US FDA discusses the issues surrounding the use of patient-reported outcomes in regulatory decision making.
Michael Hoeckel joins The Lancet Oncology to discuss his latest trial on the surgical treatment of vulvar carcinoma based on the theory of ontogenetic cancer fields.
Håvard Emil Danielsen joins The Lancet Oncology to discuss his latest paper on machine learning algorithms to analyse chromatin organisation as a prognostic marker for cancer.
Ross Camidge discusses RANO's papers on clinical trial design for patients with brain metastases.
John Field discusses a European position statement on lung cancer screening using low-dose CT.
Commission co-chairs Chi Van Dang and Elizabeth M. Jaffee discuss a new Lancet Oncology Commission on cancer treatment and care in the USA.
Ricky Sharma discusses results from three prospective trials on the use of selective internal radiotherapy for liver metastases from colorectal cancer.
Samra Turajlic discusses the contribution of small insertions and deletions to tumour-specific antigen analyses.
Percy Lee discusses the impact of prior radiotherapy on the efficacy of pembrolizumab when used to treat non-small cell lung cancer.
Michele Cavo discusses the International Myeloma Working Group’s recommendations on the use of 18F-FDG PET/CT for patients with multiple myeloma and other plasma cell dyscrasias.
Lesley Seymour discusses the iRECIST guidelines for assessing tumour responses in immunotherapy trials.
Javier Torres-Roca and Louis Harrison join us to discuss their work on genome modelling and its uses in calculating the appropriate radiation dosage.
Brigitta Baumert discusses her article on quality of life in patients with high-risk, low-grade glioma.
Brian Rini discusses active surveillance for patients with metastatic renal cell carcinoma.
Shaji Kumar discusses updated consensus criteria from the International Myeloma Working Group for response and minimal residual disease assessment in multiple myeloma.
Catherine Sauvaget and Ryo Konno discuss Japan’s low uptake of screening programmes for breast and cervical cancer.
Jean-Claude Dupont and François Doz discuss ethical issues in paediatric oncology clinical trials.
Michael Taylor discusses treatment approaches to the rare brain tumour that generally affects children, medulloblastoma.
Sibylle Loibl discusses the findings and clinical implications of the GeparSepto trial.
Discussion of two new treatment approaches to indolent lymphoma and mantle-cell lymphoma, haematological diseases with generally poor response to chemotherapy.
Harry Bear discusses the use of adjuvant and neoadjuvant bevacizumab in the treatment of early breast cancer.
Ane Appelt discusses adopting a watchful waiting approach for patients with rectal cancer who achieved a clinical complete response after chemoradiotherapy.
Dr Saro Armenian discusses long term health concerns for survivors of childhood cancers.
Jeff Bradley discusses standard verses high-dose radiation in conjunction with chemotherapy for patients with phase III non-small-cell lung cancer.
Dennis Slamon discusses advances in breast cancer treatment based on data from the PALOMA trial.
Charles Bennett discusses the development and regulatory landscape of biosimilar oncology drugs.
S Vincent Rajkumar of the Mayo Clinic discusses the updated disease definition of multiple myeloma.
Daniel M Green discusses the effect of treatment for childhood cancers on male fertility.
Naomi Lee discusses new research about depression and cancer with Michael Sharpe and Jane Walker.
Robert Hills discusses a meta-analysis of gemtuzumab ozogamicin for the treatment of adult myeloid leukaemia.
Jeremy Whelan from the National Cancer Research Institute discusses the underrepresentation of teenagers and young adults in clinical cancer trials.
Paul Spiegel discusses cancer in refugees in Jordan and Syria and how the UNHCR have addressed the provision of expensive cancer treatment.
Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.
Michael Höckel joins Natalie Harrison to discuss how surgery based on ontogenetic staging is sufficient to control cervical cancer without additional radiotherapy.
Christopher Klenk and Heike E Daldrup-Link join Natalie Harrison to discuss ionising radiation-free techniques in cancer detection.
Jonathan Banks discusses the aims and implications of a study into public preferences for cancer testing.
Jayant Vaidya and Umberto Veronesi discuss the TARGIT and ELIOT trials of intraoperative radiotherapy for early breast cancer
Jesus San Miguel discusses a phase 3 trial comparing pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients with multiple myeloma.
Ole Raaschou-Nielsen discusses the association between long-term exposure to ambient air pollution and lung cancer risk.
Perry Pickhardt discusses the value of CT colonography to determine whether small colorectal polyps will progress or not.
Thorsten Kuehn discusses the SENTINA study, concerning centinel lymph node biopsy before and after neoadjuvant chemotherapy in breast cancer.
Paul Goss presents an overview of The Lancet Oncology Commission on cancer prevention in Latin America.
Yael Mosse discusses a phase I study about the potential of targeted molecular therapy for childhood cancers.
John Farley discusses a trial of the MEK inhibitor selumetinib for the treatement of low-grade serous carcinoma of the ovary and peritoneum.
Nicole Krekel discusses a trial which assesses ultrasound-guided breast conserving surgery in the management of breast cancer.
Anticancer drugs: doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours.
Asian Oncology Summit: Consensus guidelines on palliative care, kidney cancer, and colorectal cancer.
Discussion of a UK/French study into adult diabetes risk after radiation for childhood cancer.
Gustavo Ismael discusses subcutaneous versus intravenous administration of trastuzumab in patients with breast cancer.
Circulating tumour cells as a possible prognostic marker for non-metastatic breast cancer.
Matthias Kloor discusses the prevalence of mismatch repair-deficient crypt foci in Lynch syndrome.
Discussion of updated guidelines for the appropriate use of opioids in the management of cancer pain.
HLA matching of transplanted umbilical-cord blood for treating leukaemia and myelodysplastic syndrome.
Comparison of CT colonography with conventional colonoscopy for colorectal cancer screening.
Discussion of a promising antiangiogenic approach for the treatment of ovarian cancer, and other highlights from the November issue.
October highlights, including discussion of the trial about the tyrosine kinase ALK and non-small-cell lung cancer.
David Collingridge launches The Lancet Oncology Commission on delivering affordable cancer care in high-income countries.
Emma Grainger with July highlights, and an interview about a trial assessing the value of zoledronic acid in the treatment of pre-menopausal early breast cancer.
June issue highlights, including faecal blood tests to assess future colorectal cancer risk, and of the 'dangerous liaison' between cancer and tuberculosis.
May highlights, including discussion of a phase II study about the treatment of B-cell lymphoma in very old patients.
April issue highlights, including the latest developments of the breast Health Global Initiative(BHGI), including an interview with BHGI Director Benjamin Anderson.
March issue highlights, including new data from the HERA trial about long-term efficacy of herceptin for early breast cancer.
Rob Brierley with February highlights, including the prevalence of depression among cancer patients.
January highlights, including automated verses manual cytology for detection of cervical cancers.
December issue highlights, including mammography screening for younger women with familial breast cancer.
November issue highlights, including an large-scale HPV genotype analysis with implications for cervical-cancer vaccine development, and the potential for discontinuation of imatinib treatment for people with chronic myeloid leukaemia.
Includes author interview about a trial comparing sentinal-lymph-node biopsy with axillary-lymph-node dissection in breast cancer treatment.
September issue highlights, including discussion of a possible association between hepatitis B infection and non-Hodgkin lymphoma in a Korean population.
August issue highlights, including bevacizumab for NSCLC, and cancer issues among people with mental illness.
Roy Herbst discusses the Zodiac trial, a phase 3 study assessing the efficacy of vandetanib for treating advanced non-small-cell lung cancer.
Emma Grainger discusses erlotinib as maintenance treatment for lung cancer, and IGF1 and risk of breast cancer.
The role of zoledronic acid with chemotherapy for early breast cancer and other issue highlights are discussed.
April issue highlights, including a genome-wide association study of lung cancer for never smokers.
March issue highlights, including hypofractionated radiotherapy for early breast cancer.
Emma Grainger with issue highlights and Kathy Albain discussing chemotherapy and tamoxifen for post-menopausal women with breast cancer.
Audrey Ceschia discusses issue highlights, including impact of HIV infection on cancer risk.
Discussion of new oncology management guidelines derived from didactic workshops at the Asia Oncology Summit 2009.
Rob Brierley discusses an antithrombolic agent for patients receiving chemotherapy for solid tumours.
Discussion of prostate cancer treatment, the PASSION-P trial, and a new Quackery column.
Rob Brierley discusses sunitinib for kidney cancer, and how bureaucracy is stifling UK clinical research.
Emma Grainger discusses bariatric surgery, weight loss, and cancer risk for obese people.
Audrey Ceschia discusses issue highlights, including treatment for nausea and vomiting from chemotherapy.
David Collingridge discusses research articles on prophylactic cranial irradiation for small-cell lung cancer, and the addition of temozolomide to radiotherapy for treating glioblastoma.
Rob Brierley discusses research articles on cancer survival in England, and the potential for ovarian cancer screening.
Emma Grainger discusses articles on myelodysplastic syndromes, circulating tumour cells and prostate cancer, and palliative stents for oesophageal cancer.
Rob Brierley discusses two research articles investigating genetic subtypes of childhood acute lymphoblastic leukaemia.
Emma Grainger discusses liver transplantation criteria, sorafenib for liver cancer in the Asia-Pacific, and NICE guidance on erlotinib for non-small-cell lung cancer.
David Collingridge discusses a research article comparing microsurgery with total excision for basal-cell carcinoma of the face, and other content highlights.
Rob Brierley introduces the latest issue, including research articles about prostate cancer and a review highlighting the importance of appropriate palliative care.
John Sellors and Guglielmo Ronco discuss HPV screening for precursors of cervical cancer.
Sally van der Meer discusses highlights from the September journal in this issue's podcast, including a new treatment option for preventing bone mineral loss among pre-menopausal women receiving hormone therapy for early breast cancer.
The Lancet Oncology podcast - a global health theme for the August issue. Editor David Collingridge discusses the highlights, including cancer survival from five continents, and a review of cancer issues in Africa.
TLO Editor David Collingridge discusses some highlights from the July issue: radiofrequency ablation showing promise for the treatment of lung cancer; how a rare form of obesity could negatively affect treatment outcomes; and a discussion of a recent meeting at IARC in Lyon, France, concerning the latest evidence on smoke-free policies and the effects on public health.
Emma Cannell and Sally van der Meer discuss highlights from the June issue: a prospective pilot study assessing the role of stellate-ganglion block to treat hot flushes in survivors of breast cancer; also discussed is a Personal View about cancer of unknown primary (CUP), and the Leading Edge on public confidence in Merck's HPV vaccine.
Editor David Collingridge discusses highlights from the May issue: the natural history of cervical intraepithelial neoplasia; the effect of screening on prostate-cancer mortality in the USA and UK; and the launch of a series of reviews about cancer in indigenous populations, starting this month with cancer among indigenous Polynesians.
Editor David Collingridge discusses highlights from the April issue including: encouraging results from the START trials suggest fewer fractions of radiotherapy could revolutionise treatment of early stage breast cancer; how a phase II study investigating yttrium-90 labelled ibritumomab could have an important future role in the treatment of follicular non-Hodgkin lymphoma, and finally the pressing need for increased recruitment of adolescents and young adults in to cancer trials.
Dr David Collingridge, Editor of the Lancet Oncology, discusses highlights of the March issue in the first Lancet Oncology podcast. Two main topics are discussed: a research article highlighting how individuals in the United States who are under-insured or who have no medical insurance are at an increased risk of presenting with late-stage cancers; non-whites are at a similarly increased cancer risk. Also featured is a Dutch study showing the potential benefits of a shared-care programme between family doctors and oncology clinics for the long-term follow-up of individuals diagnosed with cancer in childhood.